Abstract
The mechanisms responsible for the switch of prostate cancer from androgen-sensitive (AS) to androgen-insensitive (AI) form are not well understood. Regulation of androgen receptor (AR), through which androgens control the expression of genes involved in prostate cells proliferation, migration and death also involves its cross-talk with the other signaling pathways, transcription factors and coregulatory proteins, such as β-catenin. With the aim to determine their possible contribution in triggering the switch from AS to AI form, which occurs upon androgen deprivation therapy - AR, Akt and β-catenin expression were knocked-down with respective siRNAs. Treatment of LNCaP prostate cells with siRNA for AR significantly reduced their proliferation (45-70%), expression of nuclear β- catenin, cyclin-D1, cyclin-G1, c-Myc as well as activity of metalloproteinases (MMPs) -2,-7,-9 and cell migration. Surprisingly, after longer (over 72 hrs) silencing of AR in LNCaP cells, elevated levels of p-Akt were detected and enhanced proliferation as well as expression of nuclear β-catenin, cyclin-D1, c-Myc and activity of MMPs were observed. Such effects were not observed in either PC-3 or DU145 AI cells. However, silencing of Akt and /or β-catenin in those as well as in LNCaP cells led to their decreased proliferation and migration. Our findings suggest that in prostate cancer cells, either AR or Akt signaling prevails, depending on their initial androgen sensitivity and its availability. In AI prostate cancer cells, Akt takes over the role of AR and more effectively contributes through the same signaling molecule, β-catenin, to AI cancer progression.
Keywords: Akt, androgen-insensitive, androgen-sensitive, androgen receptor, β-catenin, metalloproteinases, prostate cancer, cyclin-D1, c-Myc, siRNA
Current Medicinal Chemistry
Title:Increased Akt Signaling Resulting from the Loss of Androgen Responsiveness in Prostate Cancer
Volume: 20 Issue: 1
Author(s): J. Dulinska-Litewka, J.A. McCubrey and P. Laidler
Affiliation:
Keywords: Akt, androgen-insensitive, androgen-sensitive, androgen receptor, β-catenin, metalloproteinases, prostate cancer, cyclin-D1, c-Myc, siRNA
Abstract: The mechanisms responsible for the switch of prostate cancer from androgen-sensitive (AS) to androgen-insensitive (AI) form are not well understood. Regulation of androgen receptor (AR), through which androgens control the expression of genes involved in prostate cells proliferation, migration and death also involves its cross-talk with the other signaling pathways, transcription factors and coregulatory proteins, such as β-catenin. With the aim to determine their possible contribution in triggering the switch from AS to AI form, which occurs upon androgen deprivation therapy - AR, Akt and β-catenin expression were knocked-down with respective siRNAs. Treatment of LNCaP prostate cells with siRNA for AR significantly reduced their proliferation (45-70%), expression of nuclear β- catenin, cyclin-D1, cyclin-G1, c-Myc as well as activity of metalloproteinases (MMPs) -2,-7,-9 and cell migration. Surprisingly, after longer (over 72 hrs) silencing of AR in LNCaP cells, elevated levels of p-Akt were detected and enhanced proliferation as well as expression of nuclear β-catenin, cyclin-D1, c-Myc and activity of MMPs were observed. Such effects were not observed in either PC-3 or DU145 AI cells. However, silencing of Akt and /or β-catenin in those as well as in LNCaP cells led to their decreased proliferation and migration. Our findings suggest that in prostate cancer cells, either AR or Akt signaling prevails, depending on their initial androgen sensitivity and its availability. In AI prostate cancer cells, Akt takes over the role of AR and more effectively contributes through the same signaling molecule, β-catenin, to AI cancer progression.
Export Options
About this article
Cite this article as:
Dulinska-Litewka J., McCubrey J.A. and Laidler P., Increased Akt Signaling Resulting from the Loss of Androgen Responsiveness in Prostate Cancer, Current Medicinal Chemistry 2013; 20 (1) . https://dx.doi.org/10.2174/0929867311302010014
DOI https://dx.doi.org/10.2174/0929867311302010014 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
Current advances in inherited cardiomyopathy
Describe in detail all novel advances in multimodality imaging related to inherited cardiomyopathy diagnosis and prognosis. Shed light to deeper phenotypic characterization. Acknowledge recent advances in genetics, genomics and precision medicineread more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Radionuclide Based Imaging of Prostate Cancer
Current Topics in Medicinal Chemistry Nature: A Substantial Source of Auspicious Substances with Acetylcholinesterase Inhibitory Action
Current Neuropharmacology Immune Mechanism, Aging, Season and Diseases: Modulatory Role of Melatonin
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Nutritional and Therapeutic Potential of Garlic and Onion (Allium sp.)
Current Nutrition & Food Science Phosphorothioate Oligonucleotides: Effectiveness and Toxicity
Current Drug Targets Recent Clinical Aspects of Hyperprolactinemia Induced by Antipsychotics
Reviews on Recent Clinical Trials PDE-5 Inhibitors for BPH-Associated LUTS
Current Drug Targets Antinociceptive Effects of VV-Hemorphin-5 Peptide Analogues Containing Amino phosphonate Moiety in Mouse Formalin Model of Pain
Protein & Peptide Letters Effects of Iron Chelation in Osteosarcoma
Current Cancer Drug Targets Review and Research Analysis of Computational Target Methods Using BioRuby and In silico Screening of Herbal Lead Compounds Against Pancreatic Cancer Using R Programming
Current Drug Metabolism Central Insulin and Insulin-Like Growth Factor-1 Signaling - Implications for Diabetes Associated Dementia
Current Diabetes Reviews Peptide Self-Assemblies for Drug Delivery
Current Topics in Medicinal Chemistry CD36 as a Therapeutic Target for Endothelial Dysfunction in Stroke
Current Pharmaceutical Design Polyploidy: The Link Between Senescence and Cancer
Current Pharmaceutical Design Magnetic Nanoparticles: New Players in Antimicrobial Peptide Therapeutics.
Current Protein & Peptide Science Ionic Liquids, Microextraction Methods and Capillary Electrophoresis in Biomedical Research
Current Pharmaceutical Analysis Meet Our Editorial Board Member:
Current Cancer Therapy Reviews Generation of Human Single-chain Antibody to the CD99 Cell Surface Determinant Specifically Recognizing Ewing’s Sarcoma Tumor Cells
Current Pharmaceutical Biotechnology Current Approaches for the Treatment with Thyroid Hormone Analogs
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery 4-Hydroxynonenal in the Pathogenesis and Progression of Human Diseases
Current Medicinal Chemistry